SREN Stock Analysis: Swiss Re | SW

Insurance - Reinsurance | SW, Switzerland | Market Cap: 39.667m CHF | 12M Return: -2.1% | Charts, Fundamentals & Technical Analysis

Property Reinsurance, Casualty Reinsurance, Life Insurance, Health Insurance
Total Rating 48
Safety 24
Buy Signal 0.45
Insurance - Reinsurance
Industry Rotation: +10.1
Market Cap: 48.7B
Avg Turnover: 104M
Risk 3d forecast
Volatility22.9%
VaR 5th Pctl3.86%
VaR vs Median2.78%
Reward TTM
Sharpe Ratio-0.23
Rel. Str. IBD41.2
Rel. Str. Peer Group27
Character TTM
Beta0.214
Beta Downside-0.027
Hurst Exponent0.423
Drawdowns 3y
Max DD22.36%
CAGR/Max DD0.87
CAGR/Mean DD3.11

Warnings

No concerns identified

Tailwinds

Shakeout

Seasonality 10.5 years of data

Jan +1.4% 17
Feb +2.4% 28
Mar -0.6% 11
Apr -0.0% 2
May -1.8% 16
Jun -2.6% 29
Jul -1.1% 24
Aug -1.8% 6
Sep -0.7% 21
Oct -0.2% 5
Nov +1.9% 9
Dec -1.7% 21

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: SREN Swiss Re

Swiss Re AG is a global reinsurer founded in 1863 and headquartered in Zurich, Switzerland. The company operates through three main segments: Property & Casualty Reinsurance, Life & Health Reinsurance, and Corporate Solutions, offering risk transfer solutions across multiple lines including property, casualty, aviation, marine, cyber, and life and health products.

Swiss Re serves a broad client base that includes stock and mutual insurance companies, public sector and governmental entities, mid-sized and large corporations, and individuals. As a reinsurer, the company essentially provides insurance to insurance companies, helping primary insurers manage large or catastrophic risks by assuming portions of their underwriting exposure.

Headlines to Watch Out For
  • P&C renewal pricing softens amid easing market conditions
  • Major catastrophe losses pressure combined ratio
  • Higher fixed income yields lift net investment income
Piotroski VR-10 (Strict) 4.0
Net Income: 3.53b TTM > 0 and > 6% of Revenue
FCF/TA: 0.02 > 0.02 and ΔFCF/TA -0.10 > 1.0
NWC/Revenue: -208.2% < 20% (prev 21.13%; Δ -229.3% < -1%)
CFO/TA 0.02 > 3% & CFO 3.16b > Net Income 3.53b
Net Debt (6.23b) to EBITDA (13.5b): 0.46 < 3
Current Ratio: 0.15 > 1.5 & < 3
Outstanding Shares: last fiscal year (298.8m) vs prev 1.16% < -2%
Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin)
Asset Turnover: 27.20% > 50% (prev 17.24%; Δ 9.96% > 0%)
Interest Coverage Ratio: 39.71 > 6 (EBIT TTM 13.5b / Interest Expense TTM 339.1m)
Altman Z'' -2.01
A: -0.55 (Total Current Assets 13.2b - Total Current Liabilities 87.1b) / Total Assets 134b
B: 0.21 (Retained Earnings 27.7b / Total Assets 134b)
C: 0.10 (EBIT TTM 13.5b / Avg Total Assets 131b)
D: 0.23 (Book Value of Equity 24.7b / Total Liabilities 109b)
Altman-Z'' = -2.01 = D
Beneish M 0.27
DSRI: 3.0 (Receivables 10.4b/624.0m, Revenue 35.5b/21.9b)
GMI: 1.0 (GM 100.0% / 100.0%)
AQI: 3.03 (AQ_t 0.90 / AQ_t-1 0.30)
SGI: 1.62 (Revenue 35.5b / 21.9b)
TATA: 0.00 (NI 3.53b - CFO 3.16b) / TA 134b)
Beneish M = 0.27 (Cap -4..+1) = D
What is the price of SREN shares?

As of July 28, 2026, the stock is trading at CHF 136.45 with a total of 651,081 shares traded. Over the past week, the price has changed by +0.81%, over one month by +5.57%, over three months by +7.36% and over the past year by -2.08%.

Current recommended Stop Loss: 133.00 (which is 2.5% or 1.3 ATR below the current price).

Is SREN a buy, sell or hold?

Swiss Re has no consensus analysts rating.

Swiss Re (SREN) - Fundamental Data Overview as of 26 July 2026
Market Cap USD = 48.7b (39.7b CHF * 1.2277 CHF.USD)
Market Cap USD = 48.7b (39.7b CHF * 1.2277 CHF.USD)
P/E Trailing = 10.4832
P/E Forward = 8.5911
P/S = 0.9357
P/B = 1.8802
P/EG = 0.8009
Revenue TTM = 35.5b USD
EBIT TTM = 13.5b USD
EBITDA TTM = 13.5b USD
Long Term Debt = 8.54b USD (from longTermDebt, last quarter)
Short Term Debt = 294.8m USD (from shortTermDebt, last quarter)
Debt = 8.98b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 6.23b USD (calculated: Debt 8.98b - CCE 2.74b)
Enterprise Value = 54.9b USD (48.7b + Debt 8.98b - CCE 2.74b)
Interest Coverage Ratio = 39.71 (Ebit TTM 13.5b / Interest Expense TTM 339.1m)
EV/FCF = 17.36x (Enterprise Value 54.9b / FCF TTM 3.16b)
FCF Yield = 5.76% (FCF TTM 3.16b / Enterprise Value 54.9b)
FCF Margin = 8.91% (FCF TTM 3.16b / Revenue TTM 35.5b)
Net Margin = 9.93% (Net Income TTM 3.53b / Revenue TTM 35.5b)
 Gross Margin = unknown ((Revenue TTM 35.5b - Cost of Revenue TTM 0.0) / Revenue TTM)
 Tobins Q-Ratio = 0.41 (Enterprise Value 54.9b / Total Assets 134b)
Interest Expense / Debt = 3.78% (Interest Expense 339.1m / Debt 8.98b)
Taxrate = 24.11% (1.11b / 4.62b)
NOPAT = 10.2b (EBIT 13.5b * (1 - 24.11%))
Current Ratio = 0.15 (Total Current Assets 13.2b / Total Current Liabilities 87.1b)
Debt / Equity = 0.36 (Debt 8.98b / totalStockholderEquity, last quarter 24.7b)
Debt / EBITDA = 0.46 (Net Debt 6.23b / EBITDA 13.5b)
Debt / FCF = 1.97 (Net Debt 6.23b / FCF TTM 3.16b)
Total Stockholder Equity = 23.5b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.70% (Net Income 3.53b / Total Assets 134b)
RoE = 15.01% (Net Income TTM 3.53b / Total Stockholder Equity 23.5b)
RoCE = 42.04% (EBIT 13.5b / Capital Employed (Equity 23.5b + L.T.Debt 8.54b))
RoIC = 22.54% (NOPAT 10.2b / Invested Capital 45.3b)
WACC = 6.13% (E(48.7b)/V(57.7b) * Re(6.73%) + D(8.98b)/V(57.7b) * Rd(3.78%) * (1-Tc(0.24)))
Discount Rate = 6.73% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -19.49 | Cagr: -0.01%
[DCF] Terminal Value 75.58% ; FCFF base≈3.15b ; Y1≈3.19b ; Y5≈3.44b
[DCF] Fair Price = 160.0 (EV 53.4b - Net Debt 6.23b = Equity 47.2b / Shares 294.9m; r=8.35% [WACC [floored]]; 5y FCF grow 1.08% → 2.50% )
EPS Correlation: 76.91 | EPS CAGR: 26.29% | SUE: 0.94 | # QB: 1
Revenue Correlation: -65.67 | Revenue CAGR: -22.29% | SUE: 3.42 | # QB: 1
EPS current Quarter (2026-06-30): EPS=4.01 | Chg30d=+3.86% | Revisions=+25% | Analysts=2
EPS next Quarter (2026-09-30): EPS=3.78 | Chg30d=-4.26% | Revisions=-25% | Analysts=2
EPS current Year (2026-12-31): EPS=16.05 | Chg30d=-1.02% | Revisions=+40% | GrowthEPS=+2.4% | GrowthRev=-1.0%
EPS next Year (2027-12-31): EPS=15.97 | Chg30d=-0.10% | Revisions=+0% | GrowthEPS=-0.5% | GrowthRev=+1.1%
[Analyst] Revisions Ratio: +22% (up=4, down=2)